EN DE
Watch Bioextrax AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bioextrax AB (BIOEX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Bioextrax AB stock SEK 1.17, price SEK 2.30, that is 49.1% below the price, quality 37 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials SE · ISIN SE0016276752

BA Bioextrax AB logo Thin data Nov 10, 2026

Bioextrax AB

BIOEX · ST
Very expensive, weak quality

Our calculation puts a fair price 49% below what the stock costs today.

Mixed Growth (revenue 5y +103.3 %/yr in SEK)
Revenue last quarter 55% below a year ago.
Fair value kr 1.17 · Strongly overvalued
Quality 37/100
Negative free cash flow
Trails peers (0/6)
Narrow moat 12/100
Thin data
Estimate
Watch Bioextrax AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 90.00 kr 1.75 Fair Value kr 1.17 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 1.75 – kr 90.00 · fair‑value band kr 0.8800 – kr 1.46 · the kr 2.30 price screens above the kr 1.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Bioextrax in your weekly email

Every Wednesday you see whether Bioextrax is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. The company harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids, as well as microfibers from feathers.

Show moreShow less

Bioextrax AB (publ) was incorporated in 2014 and is based in Lund, Sweden.

Stock analysis

Bioextrax AB (BIOEX) currently trades at kr 2.30, while our estimate is kr 1.17, 49% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.8800 (bear) to kr 1.46 (bull), the price of kr 2.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Industrials sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Bioextrax AB reported revenue of 757K SEK in FY2025 versus 276K SEK in FY2021, a compound +28.7%/yr. Reported net income was −17.7M SEK in FY2025.

Key figures

Market cap 109M SEK (≈ $11.1M) Micro · EPS (TTM) kr −0.4400 · Return on equity −124% · Return on assets (EBIT) −74.9% (5-year average) · Operating margin −2,028% · Revenue (TTM) 1.0M SEK · Revenue growth (YoY) −55.4% · Free cash flow −26.2M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −19% fair-value upside, at −49%, BIOEX screens richer than that median.

Fair Value

Bear kr 0.8800 Fair Value kr 1.17 Bull kr 1.46
Price kr 2.30 · Downside -49.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 22
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 14
How calm the share price moves, does not count
Price momentum 39
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 42
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+47.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+103.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+71.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26,386.7% (2020) → −2,426.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BIOEX screens overvalued: fair value 49% below the price. Compare with Waste Management, Inc →

Compare Bioextrax AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Waste Management · 166 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −49.1% · Bottom 25%
Profitability
Return on assets −71.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −55.4% · Bottom 25%

Valuation Multiplesvs Waste Management median · lower = cheaper

P/B 5.16× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Waste Management stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Waste Management, Inc WM $237.38 $260.27 +10% vs BIOEX
Waste Connections, Inc WCN $191.14 $199.18 +4% vs BIOEX
Fomento de Construcciones y Contratas, S.A FCC €10.54 €9.99 −5% vs BIOEX
GEM Co 002340 ¥5.71 ¥5.27 −8% vs BIOEX
GFL Environmental Inc GFL $42.41 $34.54 −19% vs BIOEX
Veolia Environnement SA VIE €34.29 €20.39 −41% vs BIOEX
Clean Harbors, Inc CLH $290.04 $155.54 −46% vs BIOEX
Republic Services, Inc RSG $247.62 $129.29 −48% vs BIOEX
Cleanaway Waste Management Limited CWY A$3.01 A$1.25 −58% vs BIOEX
Casella Waste Systems, Inc CWST $93.00 $14.30 −85% vs BIOEX

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioextrax AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bioextrax AB Fair Value". https://www.fairvalue-calculator.com/stock/BIOEX

Frequently asked questions

Is Bioextrax AB (BIOEX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 1.17 versus a price of kr 2.30, about 49% lower (overvalued).
What is the fair value of BIOEX?
Our estimate for Bioextrax AB is kr 1.17 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 2.30.
What is the quality score of BIOEX?
Bioextrax AB has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioextrax AB (BIOEX)?
Our calculated price target is the estimate of kr 1.17 (as of Nov 10, 2026). Cautious scenario kr 0.8800, optimistic scenario kr 1.46. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Bioextrax AB stock forecast for 2026?
Our estimate puts fair value at kr 1.17, about 49% lower versus a price of kr 2.30 (overvalued). Cautious scenario kr 0.8800, optimistic scenario kr 1.46. The calculation is refreshed regularly with new filings.
What is the revenue of Bioextrax AB (BIOEX)?
Bioextrax AB reported trailing-twelve-month revenue of about 1.0M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Bioextrax AB (BIOEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioextrax AB it is kr 1.17 per share (as of Nov 10, 2026), against a price of kr 2.30.
Is Bioextrax AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BIOEX trades above its calculated fair value: price kr 2.30, fair value kr 1.17, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOEX?
No. The price is what the market pays today (kr 2.30); the fair value is what the company's own numbers justify (kr 1.17). For Bioextrax AB the two are kr 1.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioextrax AB worth?
The market values Bioextrax AB at about 109M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 2.30; our models calculate a fair value of kr 1.17 per share.
What do the bullish and bearish scenarios say about BIOEX?
Our models span a range for Bioextrax AB: cautious scenario kr 0.8800, base kr 1.17, optimistic kr 1.46 per share (as of Nov 10, 2026, price kr 2.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bioextrax AB (BIOEX)?
Balance-sheet figures for Bioextrax AB (as of Nov 10, 2026): return on equity −124.0%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BIOEX from its 52-week high?
Bioextrax AB trades at kr 2.30, about 28% below its 52-week high of kr 3.19 and 29% above the low of kr 1.78 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.17 is for.
Which stocks are comparable to Bioextrax AB?
From the same area (Industrials) we also value Waste Management, Inc, Republic Services, Inc, Waste Connections, Inc, Veolia Environnement SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioextrax AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 2.30, calculated fair value kr 1.17 (−49%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Bioextrax AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioextrax AB (BIOEX)?
The closing price on Nov 10, 2026 was kr 2.30. Our estimate is kr 1.17, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioextrax AB right now?
The price sits above even our optimistic bull case (kr 1.46). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Bioextrax AB

How large is the market capitalisation of Bioextrax AB (BIOEX)?
The market capitalisation of Bioextrax AB is 109M SEK (≈ $11.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Bioextrax AB (BIOEX)?
Earnings per share at Bioextrax AB are kr −0.4400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Bioextrax AB (BIOEX)?
The return on equity (ROE) of Bioextrax AB is −124% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioextrax AB (BIOEX)?
On an EBIT basis the return on assets of Bioextrax AB is −74.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bioextrax AB (BIOEX)?
The operating margin of Bioextrax AB is −2,028% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bioextrax AB (BIOEX)?
Revenue at Bioextrax AB is growing −55.4% versus a year earlier (3y avg +24.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bioextrax AB (BIOEX) generate?
The free cash flow of Bioextrax AB is −26.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bioextrax AB (BIOEX) hold?
Bioextrax AB holds more cash than debt, 3.9M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Bioextrax AB in the live analysis

One click puts Bioextrax AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.